RecruitingPhase 2NCT03866668

A Study of Esomeprazole in Children With Autism

An Open-Label Pilot Study of Esomeprazole in Children With Autism

Sponsor

Stanford University

Enrollment

25 participants

Start Date

May 29, 2019

Study Type

INTERVENTIONAL

Conditions

Autism Autism Spectrum Disorder

Summary

Autism is a pervasive developmental disorder characterized by core deficits in social behavior and communication and the presence of repetitive/stereotyped behaviors. The objective of the study is to evaluate the efficacy of Esomeprazole as a treatment for social communication deficits in children with Autism Spectrum Disorder (ASD). This prospective 12 week open-label study will invite 25 children with ASD between the ages of 2 and 6 years of age to participate.

Eligibility

Min Age: 2 YearsMax Age: 6 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Esomeprazole for people with autism and autism spectrum disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years to 6 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEsomeprazole

Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks